缩写名/全名 |
CANCER IMMUNOL RES
Cancer Immunology Research |
||||||||||||||||||||
ISSN号 | 2326-6066 | ||||||||||||||||||||
研究方向 | ONCOLOGY-IMMUNOLOGY | ||||||||||||||||||||
影响因子 | 2015:6.665, 2016:8.284, 2017:9.188, 2018:8.619, 2019:8.728, | ||||||||||||||||||||
出版国家 | UNITED STATES | ||||||||||||||||||||
出版周期 | |||||||||||||||||||||
年文章数 | 174 | ||||||||||||||||||||
出版年份 | 0 | ||||||||||||||||||||
是否OA | No | ||||||||||||||||||||
审稿周期(仅供参考) | |||||||||||||||||||||
录用比例 | |||||||||||||||||||||
投稿链接 | https://cir.msubmit.net/cgi-bin/main.plex | ||||||||||||||||||||
投稿官网 | http://cancerimmunolres.aacrjournals.org/ | ||||||||||||||||||||
h-index | 62 | ||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2326-6066%5BISSN%5D | ||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Author: Ding L#1, Chen X#1, Xu X1, Qian Y2, Liang G1, Yao F1, Yao Z1, Wu H1, Zhang J1, He Q3, Yang B3. Journal: Cancer Immunol Res. 2019 Jan;7(1):136-149. doi: 10.1158/2326-6066.CIR-18-0071. Epub 2018 Nov 6. PubMed DOI |
2. | Calnexin Impairs the Antitumor Immunity of CD4+ and CD8+ T Cells. Author: Chen Y#1, Ma D#1, Wang X#1, Fang J1, Liu X1, Song J1, Li X1, Ren X1, Li Q1, Li Q1, Wen S1, Luo L2, Xia J1, Cui J3, Zeng G2, Chen L4, Cheng B5, Wang Z5. Journal: Cancer Immunol Res. 2019 Jan;7(1):123-135. doi: 10.1158/2326-6066.CIR-18-0124. Epub 2018 Nov 6. PubMed DOI |
3. | LncRNA-MM2P Identified as a Modulator of Macrophage M2 Polarization. Author: Cao J1, Dong R1,2, Jiang L1, Gong Y1, Yuan M1, You J1, Meng W2, Chen Z3, Zhang N4, Weng Q1, Zhu H1, He Q1, Ying M5, Yang B5. Journal: Cancer Immunol Res. 2019 Feb;7(2):292-305. doi: 10.1158/2326-6066.CIR-18-0145. Epub 2018 Nov 20. PubMed DOI |
4. | Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages. Author: Zha H1,2,3, Wang X1,2, Zhu Y1,2, Chen D1,2, Han X1,2, Yang F4, Gao J1,2, Hu C1,2, Shu C1,2, Feng Y1,2, Tan Y5, Zhang J4, Li Y6, Wan YY7, Guo B8, Zhu B9,2. Journal: Cancer Immunol Res. 2019 Feb;7(2):193-207. doi: 10.1158/2326-6066.CIR-18-0272. Epub 2018 Dec 4. PubMed DOI |
5. | LIN28/let-7/PD-L1 Pathway as a Target for Cancer Immunotherapy. Author: Chen Y#1,2, Xie C#1, Zheng X1,3, Nie X1, Wang Z2, Liu H1, Zhao Y4,2. Journal: Cancer Immunol Res. 2019 Mar;7(3):487-497. doi: 10.1158/2326-6066.CIR-18-0331. Epub 2019 Jan 16. PubMed DOI |
6. | Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Author: Xu-Monette ZY#1, Xiao M#1, Au Q#2, Padmanabhan R#3, Xu B4, Hoe N3, Rodríguez-Perales S5, Torres-Ruiz R5,6, Manyam GC7, Visco C8, Miao Y1, Tan X1, Zhang H1, Tzankov A9, Wang J7, Dybkær K10, Tam W11, You H12, Bhagat G13, Hsi ED14, Ponzoni M15, Ferreri AJM15, Møller MB16, Piris MA17, van Krieken JH18, Winter JN19, Westin JR20, Pham LV1, Medeiros LJ1, Rassidakis GZ21, Li Y22, Freeman GJ23, Young KH24,25. Journal: Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439. Epub 2019 Feb 11. PubMed DOI |
7. | Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Author: Zhao S#1, Ren S#1, Jiang T#1, Zhu B2, Li X3, Zhao C3, Jia Y1, Shi J1, Zhang L1, Liu X1, Qiao M1, Chen X1, Su C1, Yu H4, Zhou C5, Zhang J6, Camidge DR7, Hirsch FR4,8. Journal: Cancer Immunol Res. 2019 Apr;7(4):630-643. doi: 10.1158/2326-6066.CIR-17-0640. Epub 2019 Feb 12. PubMed DOI |
8. | Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. Author: Ahn S1,2, Li J3,4, Sun C1,2, Gao K3,4, Hirabayashi K2, Li H2,5, Savoldo B1,2,6, Liu R7,3,4, Dotti G8,2. Journal: Cancer Immunol Res. 2019 May;7(5):773-783. doi: 10.1158/2326-6066.CIR-18-0636. Epub 2019 Mar 6. PubMed DOI |
9. | Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Author: Zeng D#1, Li M#1, Zhou R1, Zhang J1, Sun H1, Shi M1, Bin J2, Liao Y2, Rao J3, Liao W4. Journal: Cancer Immunol Res. 2019 May;7(5):737-750. doi: 10.1158/2326-6066.CIR-18-0436. Epub 2019 Mar 6. PubMed DOI |
10. | The Pseudogene Olfr29-ps1 Promotes the Suppressive Function and Differentiation of Monocytic MDSCs. Author: Shang W1,2,3, Gao Y1,2,3, Tang Z1,2,3, Zhang Y1,2,3, Yang R4,2,3. Journal: Cancer Immunol Res. 2019 May;7(5):813-827. doi: 10.1158/2326-6066.CIR-18-0443. Epub 2019 Mar 26. PubMed DOI |
|
|